Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CASI Pharmaceuticals (CASI) Short-term Investments (2021 - 2023)

Historic Short-term Investments for Pharmaceuticals (CASI) over the last 3 years, with Q4 2023 value amounting to $12.0 million.

  • Pharmaceuticals' Short-term Investments rose 72154.58% to $12.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $12.0 million, marking a year-over-year increase of 72154.58%. This contributed to the annual value of $12.0 million for FY2023, which is 72154.58% up from last year.
  • Latest data reveals that Pharmaceuticals reported Short-term Investments of $12.0 million as of Q4 2023, which was up 72154.58% from $19.9 billion recorded in Q2 2023.
  • In the past 5 years, Pharmaceuticals' Short-term Investments registered a high of $19.9 billion during Q2 2023, and its lowest value of $1.5 million during Q4 2022.
  • For the 3-year period, Pharmaceuticals' Short-term Investments averaged around $5.0 billion, with its median value being $10.9 million (2021).
  • In the last 5 years, Pharmaceuticals' Short-term Investments plummeted by 8518.44% in 2022 and then soared by 72154.58% in 2023.
  • Pharmaceuticals' Short-term Investments (Quarter) stood at $9.9 million in 2021, then tumbled by 85.18% to $1.5 million in 2022, then skyrocketed by 721.55% to $12.0 million in 2023.
  • Its last three reported values are $12.0 million in Q4 2023, $19.9 billion for Q2 2023, and $1.5 million during Q4 2022.